Atrial Fibrillation
Conditions
Keywords
Atrial Fibrillation, Afib, cardioversion, normal sinus rhythm, arrhythmia, AF
Brief summary
This study will create a prospective registry of consecutive patients with Atrial Fibrillation (Afib) considered for cardioversion treatment to document up-to-date practice of in-hospital treatment, with a focus on the characterization of type of Afib, as well as on treatments applied (drugs, devices, interventions and their combinations), and associated complications within 60 days after enrollment.
Interventions
None listed
Sponsors
Institut für Herzinfarktforschung an der Universität Heidelberg
Merck Sharp & Dohme LLC
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant with documented atrial fibrillation (confirmed by electrocardiogram) in the hospital setting at the time of enrollment * Planned cardioversion (of atrial fibrillation)
Exclusion criteria
* Already enrolled in this or any other clinical trial * Atrial flutter
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Baseline (time of admission) | — |
| Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Baseline (time of admission) | — |
| Clinical Type of Atrial Fibrillation at Baseline (Admission) | Baseline (time of admission) | — |
| Treatments Utilized for Participants for Atrial Fibrillation | At time of Treatment (up to 1 day from admission) | — |
| Percentage of Participants Who Had a Successful Electrical or Pharmacological Cardioversion | At time of treatment (up to 1 day from admission) | Pharmacological cardioversion was considered successful if sinus rhythm or atrial rhythm was obtained within 24 hours after its initiation. Electrical cardioversion was considered successful if sinus rhythm was obtained and maintained for at least 10 minutes after the last shock was administered. |
| Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | up to 60 days from day of treatment (cardioversion) | — |
Participant flow
Recruitment details
Participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options
Participants by arm
| Arm | Count |
|---|---|
| All Enrolled Participants Participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options | 4,658 |
| Total | 4,658 |
Baseline characteristics
| Characteristic | All Enrolled Participants |
|---|---|
| Age, Continuous | 63.5 years STANDARD_DEVIATION 12.5 |
| Sex: Female, Male Female | 1742 Participants |
| Sex: Female, Male Male | 2916 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
Primary
Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission)
Time frame: Baseline (time of admission)
Population: All enrolled participants with baseline cardiovascular history data.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Male | Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Congenital Heart Disease | 1.3 Percentage of Participants |
| Male | Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Sick Sinus Syndrome | 2.3 Percentage of Participants |
| Male | Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Sustained Ventricular Tachycardia | 1.2 Percentage of Participants |
| Male | Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Ventricular Fibrillation | 0.7 Percentage of Participants |
| Female | Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Ventricular Fibrillation | 0.4 Percentage of Participants |
| Female | Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Congenital Heart Disease | 1.6 Percentage of Participants |
| Female | Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Sustained Ventricular Tachycardia | 0.5 Percentage of Participants |
| Female | Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Sick Sinus Syndrome | 3.5 Percentage of Participants |
| Total | Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Ventricular Fibrillation | 0.6 Percentage of Participants |
| Total | Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Sick Sinus Syndrome | 2.8 Percentage of Participants |
| Total | Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Sustained Ventricular Tachycardia | 0.9 Percentage of Participants |
| Total | Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Congenital Heart Disease | 1.4 Percentage of Participants |
Primary
Clinical Type of Atrial Fibrillation at Baseline (Admission)
Time frame: Baseline (time of admission)
Population: All enrolled participants with admission (baseline) atrial fibrillation data available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Male | Clinical Type of Atrial Fibrillation at Baseline (Admission) | Permanent | 4.2 Percentage of Participants |
| Male | Clinical Type of Atrial Fibrillation at Baseline (Admission) | Persistent | 36.4 Percentage of Participants |
| Male | Clinical Type of Atrial Fibrillation at Baseline (Admission) | 1st Detected Episode | 29.2 Percentage of Participants |
| Male | Clinical Type of Atrial Fibrillation at Baseline (Admission) | Paroxysmal | 27.2 Percentage of Participants |
| Male | Clinical Type of Atrial Fibrillation at Baseline (Admission) | Unknown | 3.0 Percentage of Participants |
| Female | Clinical Type of Atrial Fibrillation at Baseline (Admission) | Persistent | 27.6 Percentage of Participants |
| Female | Clinical Type of Atrial Fibrillation at Baseline (Admission) | 1st Detected Episode | 33.6 Percentage of Participants |
| Female | Clinical Type of Atrial Fibrillation at Baseline (Admission) | Paroxysmal | 31.9 Percentage of Participants |
| Female | Clinical Type of Atrial Fibrillation at Baseline (Admission) | Permanent | 3.6 Percentage of Participants |
| Female | Clinical Type of Atrial Fibrillation at Baseline (Admission) | Unknown | 3.3 Percentage of Participants |
| Total | Clinical Type of Atrial Fibrillation at Baseline (Admission) | Unknown | 3.1 Percentage of Participants |
| Total | Clinical Type of Atrial Fibrillation at Baseline (Admission) | Permanent | 4.0 Percentage of Participants |
| Total | Clinical Type of Atrial Fibrillation at Baseline (Admission) | 1st Detected Episode | 30.8 Percentage of Participants |
| Total | Clinical Type of Atrial Fibrillation at Baseline (Admission) | Persistent | 33.1 Percentage of Participants |
| Total | Clinical Type of Atrial Fibrillation at Baseline (Admission) | Paroxysmal | 28.9 Percentage of Participants |
Primary
Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission)
Time frame: Baseline (time of admission)
Population: All enrolled participants with co-morbity data available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Male | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Chronic Obstructive Pulmonary Disease | 7.8 Percentage of Participants |
| Male | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Peripheral Vascular Disease | 6.3 Percentage of Participants |
| Male | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Chronic Renal Failure | 6.7 Percentage of Participants |
| Male | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Anemia | 3.6 Percentage of Participants |
| Male | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Sleep Apnea Syndrome | 4.8 Percentage of Participants |
| Male | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Haemorrhagic Complication | 1.2 Percentage of Participants |
| Female | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Haemorrhagic Complication | 1.8 Percentage of Participants |
| Female | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Chronic Obstructive Pulmonary Disease | 7.1 Percentage of Participants |
| Female | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Anemia | 5.3 Percentage of Participants |
| Female | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Sleep Apnea Syndrome | 2.1 Percentage of Participants |
| Female | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Peripheral Vascular Disease | 5.1 Percentage of Participants |
| Female | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Chronic Renal Failure | 5.3 Percentage of Participants |
| Total | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Peripheral Vascular Disease | 5.8 Percentage of Participants |
| Total | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Chronic Renal Failure | 6.2 Percentage of Participants |
| Total | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Haemorrhagic Complication | 1.4 Percentage of Participants |
| Total | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Anemia | 4.2 Percentage of Participants |
| Total | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Chronic Obstructive Pulmonary Disease | 7.5 Percentage of Participants |
| Total | Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission) | Sleep Apnea Syndrome | 3.8 Percentage of Participants |
Primary
Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation
Time frame: up to 60 days from day of treatment (cardioversion)
Population: All enrolled participants with follow-up data available
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Death | 198 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Torsade de pointes | 0 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Minor Bleeding | 12 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Hypotension | 4 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Sick Sinus syndrome | 1 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Recurrence of Atrial Fibrillation | 107 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Peripheral Embolism | 0 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Ventricular Fibrillation | 2 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Recurrence of Atrial Flutter | 10 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Non-haemorrhagic Stroke | 7 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Symptomatic Ventricular Tachycardia | 0 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Asystole for more than 3 seconds | 2 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Bradycardia | 4 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Pulmonary Embolism | 1 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Myocardial Infarction | 2 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Tamponade | 1 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Transient Ischaemic Attack | 0 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Other Complication | 27 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Endocarditis | 0 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Heart Failure | 9 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Haemorrhagic Stroke | 1 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Syncope | 5 Participants |
| Male | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Major Bleeding | 3 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Minor Bleeding | 6 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Myocardial Infarction | 2 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Non-haemorrhagic Stroke | 3 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Haemorrhagic Stroke | 0 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Peripheral Embolism | 2 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Pulmonary Embolism | 3 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Transient Ischaemic Attack | 1 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Heart Failure | 10 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Major Bleeding | 3 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Bradycardia | 0 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Recurrence of Atrial Fibrillation | 63 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Recurrence of Atrial Flutter | 2 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Asystole for more than 3 seconds | 2 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Symptomatic Ventricular Tachycardia | 1 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Ventricular Fibrillation | 1 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Sick Sinus syndrome | 2 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Torsade de pointes | 1 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Syncope | 4 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Endocarditis | 1 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Tamponade | 0 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Hypotension | 1 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Other Complication | 18 Participants |
| Female | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Death | 113 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Major Bleeding | 6 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Hypotension | 5 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Torsade de pointes | 1 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Heart Failure | 19 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Non-haemorrhagic Stroke | 10 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Syncope | 9 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Transient Ischaemic Attack | 1 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Death | 311 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Endocarditis | 1 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Pulmonary Embolism | 4 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Other Complication | 45 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Tamponade | 1 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Peripheral Embolism | 2 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Asystole for more than 3 seconds | 4 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Recurrence of Atrial Flutter | 12 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Bradycardia | 4 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Symptomatic Ventricular Tachycardia | 1 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Recurrence of Atrial Fibrillation | 170 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Haemorrhagic Stroke | 1 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Ventricular Fibrillation | 3 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Minor Bleeding | 18 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Myocardial Infarction | 4 Participants |
| Total | Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation | Sick Sinus syndrome | 3 Participants |
Primary
Percentage of Participants Who Had a Successful Electrical or Pharmacological Cardioversion
Pharmacological cardioversion was considered successful if sinus rhythm or atrial rhythm was obtained within 24 hours after its initiation. Electrical cardioversion was considered successful if sinus rhythm was obtained and maintained for at least 10 minutes after the last shock was administered.
Time frame: At time of treatment (up to 1 day from admission)
Population: Participants who had artrial fibrillation treated by either electrical or pharmacological cardioversion.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Male | Percentage of Participants Who Had a Successful Electrical or Pharmacological Cardioversion | Electrical Cardioversion | 69.5 Percentage of Participants |
| Male | Percentage of Participants Who Had a Successful Electrical or Pharmacological Cardioversion | Pharmacological Cardioversion | 30.5 Percentage of Participants |
| Female | Percentage of Participants Who Had a Successful Electrical or Pharmacological Cardioversion | Electrical Cardioversion | 55.1 Percentage of Participants |
| Female | Percentage of Participants Who Had a Successful Electrical or Pharmacological Cardioversion | Pharmacological Cardioversion | 44.9 Percentage of Participants |
| Total | Percentage of Participants Who Had a Successful Electrical or Pharmacological Cardioversion | Electrical Cardioversion | 64.2 Percentage of Participants |
| Total | Percentage of Participants Who Had a Successful Electrical or Pharmacological Cardioversion | Pharmacological Cardioversion | 35.8 Percentage of Participants |
Primary
Treatments Utilized for Participants for Atrial Fibrillation
Time frame: At time of Treatment (up to 1 day from admission)
Population: All enrolled participants with available data pertaining to type of therapy(s) used to treat the participants atrial fibrillation.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Male | Treatments Utilized for Participants for Atrial Fibrillation | Pharmacological Cardioversion | 705 Participants |
| Male | Treatments Utilized for Participants for Atrial Fibrillation | Catheter Ablation | 92 Participants |
| Male | Treatments Utilized for Participants for Atrial Fibrillation | Pacemaker | 20 Participants |
| Male | Treatments Utilized for Participants for Atrial Fibrillation | Implantable Cardiac Defibrillator | 10 Participants |
| Male | Treatments Utilized for Participants for Atrial Fibrillation | Surgical Therapy | 1 Participants |
| Male | Treatments Utilized for Participants for Atrial Fibrillation | No Treatment | 550 Participants |
| Male | Treatments Utilized for Participants for Atrial Fibrillation | Rate Control Change | 215 Participants |
| Male | Treatments Utilized for Participants for Atrial Fibrillation | Electrical Cardioversion | 1677 Participants |
| Male | Treatments Utilized for Participants for Atrial Fibrillation | Combined Electrical/Pharmacological Cardioversion | 120 Participants |
| Female | Treatments Utilized for Participants for Atrial Fibrillation | Electrical Cardioversion | 792 Participants |
| Female | Treatments Utilized for Participants for Atrial Fibrillation | Pharmacological Cardioversion | 609 Participants |
| Female | Treatments Utilized for Participants for Atrial Fibrillation | Catheter Ablation | 32 Participants |
| Female | Treatments Utilized for Participants for Atrial Fibrillation | Combined Electrical/Pharmacological Cardioversion | 69 Participants |
| Female | Treatments Utilized for Participants for Atrial Fibrillation | Rate Control Change | 152 Participants |
| Female | Treatments Utilized for Participants for Atrial Fibrillation | Implantable Cardiac Defibrillator | 0 Participants |
| Female | Treatments Utilized for Participants for Atrial Fibrillation | Pacemaker | 18 Participants |
| Female | Treatments Utilized for Participants for Atrial Fibrillation | No Treatment | 342 Participants |
| Female | Treatments Utilized for Participants for Atrial Fibrillation | Surgical Therapy | 0 Participants |
| Total | Treatments Utilized for Participants for Atrial Fibrillation | Pacemaker | 38 Participants |
| Total | Treatments Utilized for Participants for Atrial Fibrillation | Rate Control Change | 367 Participants |
| Total | Treatments Utilized for Participants for Atrial Fibrillation | Catheter Ablation | 124 Participants |
| Total | Treatments Utilized for Participants for Atrial Fibrillation | Surgical Therapy | 1 Participants |
| Total | Treatments Utilized for Participants for Atrial Fibrillation | Implantable Cardiac Defibrillator | 10 Participants |
| Total | Treatments Utilized for Participants for Atrial Fibrillation | No Treatment | 892 Participants |
| Total | Treatments Utilized for Participants for Atrial Fibrillation | Electrical Cardioversion | 2469 Participants |
| Total | Treatments Utilized for Participants for Atrial Fibrillation | Pharmacological Cardioversion | 1314 Participants |
| Total | Treatments Utilized for Participants for Atrial Fibrillation | Combined Electrical/Pharmacological Cardioversion | 189 Participants |